Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Acquisition

 Laurus Labs has signed an investment agreement today with Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company to further acquire 7.24% stake (on fully diluted basis), subject to completion of conditions precedent, for a cash consideration of approximately Rs. 80.00 Crores. Additionally, some promoters and senior management of Laurus Labs would also acquire in ImmunoACT for a 0.54% stake (before this investment) for approximately Rs. 4 crore at same price and terms through secondary purchases. With this investment, the shareholding of the Company in ImmunoACT will become 33.86%. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations read with SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 9, 2015, is also attached as per 'Annexure'. This is for your information and record.
31-05-2023
Bigul

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of Analyst/Institutional Investor meeting scheduled on June 02, 2023 are as follows: Date: June 02, 2023 Analyst / Investors: B&K Conference - Trinity India 2023 Type of Interaction: In-Person Meetings
30-05-2023
Bigul

Laurus Labs Ltd - 540222 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 Please find enclosed the Annual secretarial compliance report required under Regulation 24A of the SEBI (LODR) Regulations, 2015, issued by the Practicing Company Secretary for the year ended March 31, 2023. This is for your information and records.
24-05-2023
Bigul

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of Analyst/Institutional Investor meeting scheduled on May 24, 2023.
20-05-2023
Bigul

Laurus Labs steps up focus on R&D with a pipeline of 60 products

 The Hyderabad-based company, which posted 6,041 crore revenue in FY23 marking a 22 per cent increase, compared to the same in the previous year, spent 3.5 per cent on overall R&D during the last financial year.
11-05-2023
Bigul

Laurus Labs Ltd - 540222 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2

 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Laurus Labs Ltd 2 CIN NO. L24239AP2005PLC047518 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2022-23, FY 2023-24, FY 2024-25 5 Incremental borrowing done in FY (T)(a) 200.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 50.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* Not Applicable 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 50 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)Not Applicable Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-G Venkateswar ReddyDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- V V Ravi Kumar Designation : -Executive Director and Chief...
09-05-2023
Bigul

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Pursuant to Regulation 30 & 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to our Results conference call intimation dated April 21, 2023, please be informed that the Results conference call for Full year and Q4 FY23 was hosted on April 27, 2023 and the Transcript of the conference call is enclosed for information and record.
03-05-2023
Bigul

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 The Company is pleased to announce that it has received the USFDA tentative approval of the World''s First Oral Dispersible Film (ODF) Dolutegravir 5mg and 10mg for Pediatric ARV treatment. This innovative paediatric drug administration through Oral Dispersible Film technology developed by Laurus Labs will simplify the drug administration in children. It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment. Laurus Labs was also the first generic approved company for a fixed dose combination of Abacavir/Dolutegravir/Lamivudine 600/50/300 mg, which is being used to treat adult HIV patients for 2nd line treatment. A press release to this extent is also enclosed for your information and records.
02-05-2023

Hold Laurus Labs; target of Rs 338: Sharekhan

 Sharekhan recommended Hold rating on Laurus Labs with a target price of Rs 338 in its research report dated April 28, 2023.
02-05-2023

Pharma stock trading at a discount of 49% from 52-week-high declares 2nd interim dividend: Check record date here

 Laurus Labs is a mid cap company recorded a market cap of 16,571.60 Cr during Friday's closing.
30-04-2023
Next Page
Close

Let's Open Free Demat Account